Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

Related Articles by Review for PubMed (Select 9674713)

1.

High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia.

Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I.

Am J Med. 1998 Jun;104(6):517-25.

PMID:
9674713
2.

Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians.

Coley CM, Barry MJ, Fleming C, Mulley AG.

Ann Intern Med. 1997 Mar 1;126(5):394-406. Review.

PMID:
9054286
3.

Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?

Hall MC, Roehrborn CG, McConnell JD.

Semin Urol Oncol. 1996 Aug;14(3):122-33. Review.

PMID:
8865473
4.

Social ecological predictors of prostate-specific antigen blood test and digital rectal examination in black American men.

Woods VD, Montgomery SB, Herring RP, Gardner RW, Stokols D.

J Natl Med Assoc. 2006 Apr;98(4):492-504. Review.

5.

Population screening for prostate cancer and emerging concepts for young men.

Moul JW.

Clin Prostate Cancer. 2003 Sep;2(2):87-97. Review.

PMID:
15040869
6.

Natural history of changes in prostate specific antigen in early stage prostate cancer.

Pearson JD, Carter HB.

J Urol. 1994 Nov;152(5 Pt 2):1743-8. Review.

PMID:
7523722
7.
8.
9.

Prostate-specific antigen testing to screen for prostate cancer.

Budenholzer BR.

J Fam Pract. 1995 Sep;41(3):270-8. Review.

PMID:
7544400
10.

The association of benign prostatic hyperplasia and cancer of the prostate.

Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP.

Cancer. 1992 Jul 1;70(1 Suppl):291-301. Review.

PMID:
1376199
11.

Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.

Parsons JK, Sarma AV, McVary K, Wei JT.

J Urol. 2009 Dec;182(6 Suppl):S27-31. doi: 10.1016/j.juro.2009.07.086. Review.

PMID:
19846130
12.

Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms--what do we know?

Sarma AV, Parsons JK, McVary K, Wei JT.

J Urol. 2009 Dec;182(6 Suppl):S32-7. doi: 10.1016/j.juro.2009.07.088. Review.

PMID:
19846144
13.

Early detection of prostate cancer. Role of prostate-specific antigen.

Prabhakaran VM.

Can Fam Physician. 1996 Apr;42:709-12. Review.

14.

Baseline prostate-specific antigen testing at a young age.

Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH.

Eur Urol. 2012 Jan;61(1):1-7. doi: 10.1016/j.eururo.2011.07.067. Epub 2011 Aug 10. Review.

PMID:
21862205
15.

Prostate-specific antigen screening: friend or foe?

Linn MM, Ball RA, Maradiegue A.

Urol Nurs. 2007 Dec;27(6):481-9; quiz 490. Review.

PMID:
18217530
16.

A review of prostate-specific antigen screening prevalence and risk perceptions for first-degree relatives of men with prostate cancer.

McDowell ME, Occhipinti S, Gardiner RA, Baade PD, Steginga SK.

Eur J Cancer Care (Engl). 2009 Nov;18(6):545-55. doi: 10.1111/j.1365-2354.2008.01046.x. Review.

PMID:
19686273
17.

Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA.

Lilja H, Stenman UH.

Cancer Treat Res. 1996;88:93-101. Review. No abstract available.

PMID:
9239474
18.

Controversies in the early detection of prostate cancer.

Montie JE.

In Vivo. 1994 May-Jun;8(3):407-11. Review.

PMID:
7528555
19.

The clinical assessment of benign prostatic hyperplasia.

Kirby RS.

Cancer. 1992 Jul 1;70(1 Suppl):284-90. Review.

PMID:
1376198
20.

Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.

Parsons JK, Sarma AV, McVary K, Wei JT.

J Urol. 2013 Jan;189(1 Suppl):S102-6. doi: 10.1016/j.juro.2012.11.029. Review.

PMID:
23234610
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk